A promising pipeline
Take a closer look at the progress of our first-in-class therapeutics.

Drug | Indication* | Phase I | Phase II | Phase III | FDA Approved | Commercialization Rights† (ex-Japan and S. Korea)‡ |
||
---|---|---|---|---|---|---|---|---|
Difelikefalin injection | Pruritus CKD-HD§ | Commercial Rights: US-Vifor EU / Other-VFMCRP|| |
US-Vifor
EU / Other-VFMCRP|| |
|||||
Oral difelikefalin | Pruritus AD | Commercial Rights: Cara |
Cara
|
|||||
Oral difelikefalin | Pruritus NDD-CKD | Commercial Rights: Cara |
Cara
|
|||||
Oral difelikefalin | Pruritus PBC | Commercial Rights: Cara |
Cara
|
|||||
Oral difelikefalin | Pruritus NP | Commercial Rights: Cara |
Cara
|
- *Cara Therapeutics has investigated difelikefalin for post-operative pain.
- †Vifor has commercial rights in Non-US Fresenius Medical Care dialysis clinics under a profit-share arrangement.
- ‡Commercialization rights to difelikefalin in defined indications—Japan: Maruishi Pharma; South Korea: CKD Pharma.
- §Approved for USA.
- ||VFMCRP and Cara have rights to promote in Fresenius clinics in the US under a profit-share agreement.
- CKD-HD: Chronic Kidney Disease-Hemodialysis; NDD—CKD: Non-Dialysis Dependent-Chronic Kidney Disease; AD: Atopic Dermatitis; PBC: Primary Biliary Cholangitis; NP: Notalgia Paresthetica.